DCPH vs. MRVI, TGTX, KROS, AMPH, GERN, VERA, ARVN, DYN, RCKT, and NAMS
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Maravai LifeSciences (MRVI), TG Therapeutics (TGTX), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Geron (GERN), Vera Therapeutics (VERA), Arvinas (ARVN), Dyne Therapeutics (DYN), Rocket Pharmaceuticals (RCKT), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Deciphera Pharmaceuticals had 20 more articles in the media than Maravai LifeSciences. MarketBeat recorded 28 mentions for Deciphera Pharmaceuticals and 8 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.75 beat Deciphera Pharmaceuticals' score of 0.13 indicating that Maravai LifeSciences is being referred to more favorably in the news media.
71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Maravai LifeSciences has a net margin of -41.19% compared to Deciphera Pharmaceuticals' net margin of -119.33%. Maravai LifeSciences' return on equity of -1.31% beat Deciphera Pharmaceuticals' return on equity.
Deciphera Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.
Deciphera Pharmaceuticals currently has a consensus target price of $24.17, suggesting a potential downside of 4.72%. Maravai LifeSciences has a consensus target price of $11.56, suggesting a potential upside of 28.25%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals received 263 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.06% of users gave Maravai LifeSciences an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Maravai LifeSciences has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Maravai LifeSciences beats Deciphera Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
